---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-26-009744"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2026-05-01T23:59:59+00:00"
generated_at: "2026-05-15T00:16:26.225415+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Tonix reports preliminary Q1 net loss $40.8M, cash $185.5M, revenue $6.9M

## Summary
- Net loss for Q1 2026 was ~$40.8M, up from $16.8M in Q1 2025; revenue rose to $6.9M from $2.4M, led by TONMYA ($3.7M).
- Cash and equivalents at March 31, 2026: $185.5M; common shares outstanding as of April 30, 2026: 15,540,801.
- Net cash used in operations was $40.2M in Q1 2026 vs $16.6M in Q1 2025; capex was $1.7M vs $6,000.
- Raised $17.4M net from equity offerings in Q2 2026; cash runway expected into Q2 2027.
- Preliminary results subject to revision; final Q1 2026 10-Q expected on or about May 11, 2026.

## SEC filing metadata
- accession: 0001999371-26-009744
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2026-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937126009744/0001999371-26-009744-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937126009744/tnxp-8k_050126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-26-009744
- JSON: https://secwatch.observer/filing/0001999371-26-009744.json
- Plain text: https://secwatch.observer/filing/0001999371-26-009744.txt

## Key facts
- Earnings Releases
  Tonix Pharmaceuticals Holding Corp. reported quarter ended March 31, 2026 results: revenue approximately $6.9 million, net income approximately $40.8 million.
  - Period: quarter ended March 31, 2026
  - Revenue: approximately $6.9 million
  - Net income: approximately $40.8 million
  - Result: preliminary results
  source text: to $16.8 million for the quarter ended March 31, 2025. · The Company’s net revenue from sales of its marketed products for the quarter ended March 31, 2026, was approximately $6.9 million compared to $2.4 million for the quarter ended March 31, 2025. o Net revenue from sales of Zembrace® SymTouch ® and Tosymra ® for the quarter ended March 31, 2026, was
  evidence_url: https://www.sec.gov/Archives/edgar/data/1430306/000199937126009744/0001999371-26-009744-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.